RADIUS HEALTH, INC. (NASDAQ:RDUS) stock is currently pricing at roughly $39.07. Our analysis shows that the stock is widely covered by equity research firms, and target prices are revealing. From a summary standpoint, we track the median one-year price target among 8 analysts covering the company at $65.50. That suggests shares of the stock may have another 40 percent to the upside left to run. Of those analysts we surveyed, the highest price target on recordsits at $85.00, which would imply another -18 percent in upside potential. If we look for a little more qualitative data on the range of expectations, we find in analyst notes that the stock has 0 “Buy” ratings in place. At the same time, 0 rate the stock a “strong buy”, suggesting more conviction in the story. As for the doubters, 0 equity research analyst firms call this stock a “Hold” and 0 consider it bad enough to warrant a “Sell” rating.

Analysts at Maxim Group took a look at RDUS shares in a research note released on Aug 04, 2016, and issued a Sell rating to this company. H.C. Wainwright analysts provided their own take on company recently as well. In a research note published on May 23, 2016,the house assigned a Buy rating to this stock. According to a piece that hit the wires on Mar 30, 2016, researchers at Goldman reconsidered their prior rating on the stock, and upped it from Perform to Neutral.

RADIUS HEALTH, INC. (RDUS) Cap Table Analysis

Breaking down the capitalization table is our next goal. From a bird’s eye view, Executives hold 0.05 percent of the stock.

If we take a more granular look, Mr. Robert E. Ward is one of the largest owners in company capital stock among insiders. According to U.S. Securities and Exchange Commission (SEC) filings, this investor owns 15,000 shares, representing a total current market value of roughly $586050. Mr. David P. Snow is another major player among company insiders, currently holding 6,000 shares as of less than 0.1%, carrying a current market value of $234420. Mr. Brent Hatzis-Schoch is currently ranked as the number three insider in terms of representation on the cap table for the stock, holding 500 shares, valued at around $19535 as of recent close.

We noted a few insider transactions for the stock recently as well.

In a transaction on 2017-03-21, the company’s 10% Owner BIOTECH GROWTH N V Purchased 50,000 company shares for 1791500. That means, once accounting for this transaction, the 10% Owner is left with a stake of 4,540,399 shares, carrying a current total market value of $177393389. In addition, by means of a transaction dated 2017-03-17, 10% Owner BIOTECH GROWTH N V purchased 30,000 shares worth $1152300. After that transaction, this investor is left with a total holding of 4,490,399 shares, representing a total investment value of $175439888.93. We also noted a 2017-03-15 transaction in which RDUS 10% Owner BIOTECH GROWTH N V purchased 61,721 shares at a stock price of $39.97, carrying a total value of $2466990, after which, this insider’s investment stands at 4,460,399 shares, with an overall financial value of $174267789.


In the company’s last quarter, RDUS EPS moved to $ from $ compared sequentially with the prior quarter. Revenues for the company came in at $M. This stacks up against $M, on a sequential basis.

How does this compare with bottom and top-line expectations? Well, according to what we could find, analysts had been looking for the company to post net income of about $ per share on $M in revenue. That sets up an interesting next quarter report card. We would note that analysts seem to be projecting earnings, on average, for this quarter in the range of $-1.60 to $0.62. On a year-over-year basis, that compares with an EPS comp of $.

Subscribe to our Newsletter

Join our mailing list to receive the latest news and updates from our team.